These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11975712)

  • 1. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus.
    Vella A; Lee JS; Camilleri M; Szarka LA; Burton DD; Zinsmeister AR; Rizza RA; Klein PD
    Neurogastroenterol Motil; 2002 Apr; 14(2):123-31. PubMed ID: 11975712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.
    Kong MF; Stubbs TA; King P; Macdonald IA; Lambourne JE; Blackshaw PE; Perkins AC; Tattersall RB
    Diabetologia; 1998 May; 41(5):577-83. PubMed ID: 9628276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
    Kong MF; King P; Macdonald IA; Stubbs TA; Perkins AC; Blackshaw PE; Moyses C; Tattersall RB
    Diabetologia; 1997 Jan; 40(1):82-8. PubMed ID: 9028722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.
    Samsom M; Szarka LA; Camilleri M; Vella A; Zinsmeister AR; Rizza RA
    Am J Physiol Gastrointest Liver Physiol; 2000 Jun; 278(6):G946-51. PubMed ID: 10859225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?
    Asmar M; Bache M; Knop FK; Madsbad S; Holst JJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2367-75. PubMed ID: 20194711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramlintide: A new tool in diabetes management.
    Want LL; Ratner RE
    Curr Diab Rep; 2006 Nov; 6(5):344-9. PubMed ID: 17076994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.
    Weyer C; Maggs DG; Young AA; Kolterman OG
    Curr Pharm Des; 2001 Sep; 7(14):1353-73. PubMed ID: 11472273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramlintide. AC 137, ACO 137, Normylin, Symlin, Tripro-amylin.
    Drugs R D; 1999 Aug; 2(2):118-22. PubMed ID: 10820656
    [No Abstract]   [Full Text] [Related]  

  • 11. Pramlintide: (AC 137, AC 0137, Symlin, Tripro-Amylin).
    BioDrugs; 2003; 17(1):73-9. PubMed ID: 12534323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amylin and the gastrointestinal tract.
    Macdonald IA
    Diabet Med; 1997 Jun; 14 Suppl 2():S24-8. PubMed ID: 9212326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
    Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
    Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of gastric emptying.
    Young A
    Adv Pharmacol; 2005; 52():99-121. PubMed ID: 16492543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
    Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
    Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramlintide acetate.
    McQueen J
    Am J Health Syst Pharm; 2005 Nov; 62(22):2363-72. PubMed ID: 16278328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk.
    Hoogwerf BJ; Doshi KB; Diab D
    Vasc Health Risk Manag; 2008; 4(2):355-62. PubMed ID: 18561511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes.
    Kellmeyer TA; Kesty NC; Wang Y; Frias JP; Fineman MS
    J Clin Pharmacol; 2007 Jul; 47(7):798-805. PubMed ID: 17463219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.
    Orskov L; Nyholm B; Yde Hove K; Gravholt CH; Møller N; Schmitz O
    Diabet Med; 1999 Oct; 16(10):867-74. PubMed ID: 10547215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.